NASDAQ · PRE
Prenetics Global Limited
$18.98+$0.46 (+2.48%)
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
Loading market information…
OTC · OCEA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ocean Biomedical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Ocean Biomedical, Inc.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$1.44. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ocean Biomedical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are specifically designed to target Chi3l1, offering potential treatments for non-small cell lung cancer and glioblastoma multiforme. Additionally, they are progressing a small molecule drug candidate aimed at Chit1, intended to address Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Leveraging its proprietary WPDS platform, Ocean Biomedical is also developing three further product candidates. These encompass a promising malaria vaccine, a humanized mAb therapeutic for malaria that targets the Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic also designed to interact with PfGARP. Furthermore, a treatment candidate for hospitalized COVID-19 patients is also under development. The company, established in 2019, maintains its operations in Providence, Rhode Island.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q2 2023 | Aug 14, 2023 | -$0.39-95.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$18.98+$0.46 (+2.48%)
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
$29.46-$0.89 (-2.93%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.13% below the high.
CA$4.65-CA$0.21 (-4.32%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 74.17% below the high.
$0.37-$0.02 (-5.95%)
Pasithea Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.06% below the high.
$2.91-$0.42 (-12.61%)
NLS Pharmaceutics AG’s quoted price sits in the lower half of its reported 52-week range, 93.29% below the high.
$0.01$0.00 (0.0%)
CERo Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.76% below the high.
$0.02$0.00 (0.0%)
Vincerx Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.95% below the high.
